Conference Coverage

VIDEO: PCSK9 inhibitors placed in perspective


 

AT ACC 14

WASHINGTON – "We’re at the dawn of an era of biological therapeutics in cardiology," Dr. Peter Libby, chief of cardiovascular medicine at the Brigham and Women’s Hospital in Boston, told us at the annual meeting of the American College of Cardiology, as he provided the lowdown on the potentially game-changing novel class of LDL cholesterol–lowering medications known as PCSK9 inhibitors.

One such agent, evolocumab, was the focus of five highly positive phase III clinical trials presented at ACC 14.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

bjancin@frontlinemedcom.com

Recommended Reading

Cooling the resuscitated sudden dead
MDedge Family Medicine
FDA: Naproxen may pose lower CV risk
MDedge Family Medicine
Persistent depression doubled coronary heart disease risk
MDedge Family Medicine
FDA reviewers support approval of platelet inhibitor cangrelor for PCI indication
MDedge Family Medicine
NSAID makers argue against new warnings on CV risks
MDedge Family Medicine
No new cardiovascular warnings needed for NSAIDs say FDA advisers
MDedge Family Medicine
FDA panel votes against cangrelor approval for PCI, bridge indications
MDedge Family Medicine
USPSTF: Insufficient evidence to judge vitamin supplements
MDedge Family Medicine
'Revolutionary' LDL lowering shown in evolocumab phase III trials
MDedge Family Medicine
VIDEO: Novel drug misses mark for MI prevention, but shows promise
MDedge Family Medicine

Related Articles